- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06220669
En undersøgelse af LY3541860 hos voksne deltagere med recidiverende multipel sklerose
En adaptiv fase 2a/2b, randomiseret, dobbeltblind, parallelgruppeundersøgelse til at undersøge sikkerheden og effektiviteten af LY3541860 sammenlignet med placebo til at bremse forekomsten af nye T1 Gadolinium-forstærkende læsioner hos voksne deltagere med recidiverende multipel sklerose
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Nottingham, Det Forenede Kongerige, NG7 2UH
- Queen's Medical Centre
-
-
-
-
Florida
-
Gulf Breeze, Florida, Forenede Stater, 32561
- Panhandle Research and Medical Clinic
-
Winter Park, Florida, Forenede Stater, 32789
- Conquest Research LLC - Winter Park - ClinEdge - PPDS
-
-
Illinois
-
Northbrook, Illinois, Forenede Stater, 60062
- Consultants in Neurology
-
-
Missouri
-
Ozark, Missouri, Forenede Stater, 65721-5315
- Sharlin Health and Neurology
-
-
South Carolina
-
Greer, South Carolina, Forenede Stater, 29605
- Premier Neurology
-
-
Tennessee
-
Knoxville, Tennessee, Forenede Stater, 37922
- Hope Neurology
-
-
-
-
-
Poissy, Frankrig, 78303
- Centre Hospitalier Intercommunal - Site de Poissy
-
-
-
-
-
Milan, Italien, 20133
- Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta-VIA MANGIAGALLI 3
-
-
-
-
-
Riga, Letland, LV-1002
- Pauls Stradins Clinical Univeristy Hospital
-
-
-
-
-
Bydgoszcz, Polen, 85-796
- Neurocentrum Bydgoszcz sp. z o.o.
-
Katowice, Polen, 40-686
- NEURO-MEDIC Sp. z o. o.
-
Katowice, Polen, 40-060
- Specjalistyczna Praktyka Lekarska prof. Grzegorz Opala
-
Katowice, Polen, 40-571
- M.A. - LEK A.M. Maciejowscy SC. Centrum Terapii SM
-
Lublin, Polen, 20-064
- Clinirem
-
Poznan, Polen, 61-853
- Niepubliczny Zaklad Opieki Zdrowotnej NEURO-KARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy
-
Warsaw, Polen, 02-677
- ETG Neuroscience - PPDS
-
Zabrze, Polen, 41-800
- IBISMED Wielospecjalistyczne Centrum Medyczne
-
Żory, Polen, 44-240
- ProNeuro Centrum Medyczne
-
-
-
-
-
Bratislava, Slovakiet, 826 06
- Nemocnica Ruzinov
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Participants must meet criteria for relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis based on the 2017 revision of the McDonald diagnostic criteria (Thompson et al. 2018) with a relapsing course (RMS) activity according to Klineova and Lublin 2018.
-
Participants must have 1 of these:
- at least 1 documented relapse within the previous year
- at least 2 documented relapses within the previous 2 years, or
- at least 1 active GdE brain lesion on an MRI scan in the past 180 days prior to screening.
-
Have an Expanded Disability Status Scale (EDSS) score of less than or equal to (≤) 5.5 at screening and randomization.
Exclusion Criteria:
-
Have had a diagnosis of:
- primary progressive multiple sclerosis (MS) according to the 2017 revision of McDonald diagnostic criteria (Thompson et al. 2018), or
- nonactive secondary progressive MS ( Klineova and Lublin 2018).
-
Meet criteria for neuromyelitis optica spectrum disorder (Wingerchuk and Lucchinetti 2022).
-
Have a history of clinically significant central nervous system (CNS) disease.
-
Have had a confirmed relapse with systemic corticosteroid administration <30 days prior to randomization.
-
Have more than 20 active GdE brain lesions on screening MRI scan.
-
Have received any of these medications or treatments.
-
Have a current or recent acute, active infection.
-
Have current serious or unstable illnesses.
-
Have any other clinically important abnormality at screening or baseline.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: LY3541860 High Dose
Participants received a high dose of LY3541860 administered intravenously (IV) over a period of 36 weeks. |
Administered IV |
|
Eksperimentel: Placebo / LY3541860 Low Dose
Participants received LY3541860-matching placebo for 12 weeks, followed by a low dose of LY3541860 administered intravenously (IV) over a period of 24 weeks. |
Administered IV Administered IV |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions
Tidsramme: 12 Weeks
|
The cumulative number of new T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1). |
12 Weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cumulative Number of Total Number of T1 GdE Lesions
Tidsramme: 12 Weeks
|
The cumulative number of total number of T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1). |
12 Weeks
|
|
Cumulative Number of New and/or Enlarging T2 Lesions
Tidsramme: 12 Weeks
|
The cumulative number of new and/or enlarging T2 lesions identified on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) approach with a negative binomial regression outcome model adjusted for geographic region (North America vs Rest of World) and presence of T1 gadolinium-enhancing lesions at baseline (0 vs ≥1). |
12 Weeks
|
|
Pharmacokinetics (PK): Observed Plasma Trough Concentrations of LY3541860 at Week 12
Tidsramme: Predose at Week 12
|
Observed Plasma trough concentrations (Ctrough) of LY3541860. |
Predose at Week 12
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 18548
- J3K-MC-KIAB (Anden identifikator: Eli Lilly and Company)
- 2023-503289-22-00 (Anden identifikator: EU Trial Number)
- 2023 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD-delingstidsramme
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD-delingsadgangskriterier
research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .